25/09/2026 J&J’s guselkumab showed significant improvement in axial PsA FDA approved Lilly's baricitinib for sever AA in paediatric patients aged 12 and older J&J’s guselkumab showed significant improvement in axial PsA (Ref) Johnson & Johnson’s TREMFYA® (guselkumab; anti-IL-23) met its primary and major secondary endpoints in the Phase 4 STAR study in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). Guselkumab significantly improved sp

27/02/2026 Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata ( Ref ) Eli Lilly and Company and Incyte announced European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for Olumiant (baricitinib; JAK inhib